Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 3.39
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell